The €42 Billion Backlog That Can't Stop the Sell-Off

The numbers at Czechoslovak Group tell a story of staggering growth—revenue up 72% last year, orders worth €42 billion in the pipeline, and a management team sticking to guidance for 2026 sales between €7.4 billion and €7.6 billion. Yet the stock tells a different tale entirely. The shares closed Wednesday at €15.60, a fresh low near the year's bottom, carving out a 30.85% monthly loss. From the January debut peak, the market capitalisation has shrunk by more than half. Investors are betting against the story, and the first quarterly report since listing is already set to be a reckoning.

The tension comes down to two open questions: when regulators will clear a planned 49% stake in Hirtenberger Defence Systems, and whether a €58 billion EU financing program called Security Action for Europe will come together before the end of May. Both are dragging on sentiment in a way that no amount of production expansion seems able to fix.

The Hirtenberger acquisition would be CSG’s first move into Austria, adding mortar systems, ammunition, optics, and digital fire control to its portfolio. It’s a classic bolt-on deal that strengthens the European production base. But the Hungarian seller, 4iG Group, is still waiting for regulatory sign-off. Until that happens, a piece of the growth narrative stays in limbo—and the market has shown little tolerance for open-ended timelines.

SAFE adds another layer of uncertainty. The Slovak ammunition framework contract, with a ceiling value of €58 billion, could be financed at a 1% interest rate through the EU program. But the mechanism requires participation from at least two member states, and that special arrangement expires at the end of May. Romania has denied ministerial-level talks, and Croatia is still weighing its decision. CSG insists the contract does not depend on any single EU funding mechanism and that it remains a framework deal, not a firm order book. Still, the deadline hangs over the stock.

Should investors sell immediately? Or is it worth buying CSG?

Operationally, fresh wins keep coming. CSG recently booked a Western European order worth nearly €250 million for 155mm artillery shells, and through Excalibur International it added air defence contracts from Southeast Asia valued at almost €2.5 billion. That puts the production capacity dispute front and centre. The short-seller Hunterbrook Media has argued that CSG’s claim of making 630,000 large-calibre rounds annually—80% of them 155mm—is inflated, estimating actual output at between 100,000 and 280,000 units based on assembly operations in Dubnica, Slovakia. CSG has pushed back, stating that internal capacity hit 630,000 rounds in 2025 without reactivation or third-party help, and that it expects a 20% increase in own production this year. A new line in Slovakia will add 70,000 rounds, and the medium-term target is 1.1 million rounds across multiple European sites and in India.

Another reputational hurdle lingers. The NATO Support and Procurement Agency blocked CSG’s Spanish subsidiary FMG from new tenders on July 31, 2025, and extended that suspension indefinitely in March. A NATO official cited standard procedure for contractors under suspicion of fraud or corruption related to NATO contracts. CSG has called the matter immaterial and noted that FMG can still sell directly to NATO member states. But the black mark adds to the barrage of questions the company must answer when it reports first-quarter numbers on May 20.

On the financing side, the picture is more encouraging. Moody’s upgraded CSG’s secured senior debt from Ba1 to Baa3 in February, praising improved governance, a simpler capital structure, and more conservative financial policies. Fitch affirmed its BBB- rating with a stable outlook. The upgrades lower future funding costs and open the door for institutional investors who require investment-grade ratings. Yet the stock has not benefited from the vote of confidence.

CSG at a turning point? This analysis reveals what investors need to know now.

Analysts remain conspicuously bullish. Nine rate the stock a buy, with no sell recommendations in sight. The average price target stands at €35.40, ranging from €31.47 to €42. That implies more than double the current share price. But the market is demanding proof, not promises. The May 20 report will be the first time CSG must back its narrative with hard numbers on margins, one-off IPO costs, Hirtenberger progress, SAFE developments, and the capacity dispute. If the numbers don't settle the open questions, the gap between the backlog and the stock price may only widen.

Ad

CSG Stock: New Analysis - 13 May

Fresh CSG information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated CSG analysis...

en | NL0015073TS8 | THE | boerse | 69324799 |